Geron Corporation (GON.F)
| Previous close | 3.2020 |
| Open | 3.2830 |
| Bid | 3.2940 x 200000 |
| Ask | 3.3640 x 200000 |
| Day's range | 3.2020 - 3.2830 |
| 52-week range | 1.5810 - 3.4850 |
| Volume | |
| Avg. volume | 650 |
| Market cap | 2.018B |
| Beta (5Y monthly) | 0.61 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Geron to Announce First Quarter 2024 Financial Results on May 2, 2024
FOSTER CITY, Calif., April 25, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results and business highlights before the market opens on Thursday, May 2, 2024 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. ET the same day.
- Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., April 18, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 243,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
- Business Wire
Geron to Participate at Upcoming Investor Conferences in April
FOSTER CITY, Calif., April 03, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following virtual investor conferences:
